According to filings with the U.S. Securities and Exchange Commission, Amytrx Therapeutics is raising up to $6,000,000.00 in new funding. Sources indicate that as part of senior management President and Chief Executive Officer, Mathew Gonda played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Amytrx Therapeutics
Amytrx Therapeutics is advancing a new class of peptide therapies to overcome inflammatory diseaseswith a vision of providing transformative medicines to patients. Drawing on 25 years of research, Amytrx is harnessing the power of novel anti-inflammatory peptide discoveries to advance new medicines aimed at the prevention and treatment of inflammatory diseases. Our lead therapeutic candidate, AMTX-100, is bioengineered from human protein sequences that modulate the immune system by a natural process, reducing pathogenesis in a range of chronic diseases mediated by excessive inflammation. Joining forces with institutions for clinical research, Amytrx Therapeutics is dedicated to transforming the conventional treatment of chronic inflammatory diseases using biological technology that is easily understood by the human body in a way that is safe, effective, and simple to use.

To learn more about Amytrx Therapeutics, visit http://www.amytrx.com/

Contact:
Mathew Gonda, President and Chief Executive Officer
205-427-8787
https://www.linkedin.com/in/matthew-a-gonda-ph-d-bb002210/

SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.